Gelteq (GELS) Competitors $1.91 +0.04 (+2.14%) As of 07/25/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GELS vs. CUE, OTLK, RPTX, INMB, QNTM, IKNA, VRCA, ICCC, HOWL, and MNOVShould you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Cue Biopharma (CUE), Oncobiologics (OTLK), Repare Therapeutics (RPTX), INmune Bio (INMB), Quantum Biopharma (QNTM), Ikena Oncology (IKNA), Verrica Pharmaceuticals (VRCA), ImmuCell (ICCC), Werewolf Therapeutics (HOWL), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry. Gelteq vs. Its Competitors Cue Biopharma Oncobiologics Repare Therapeutics INmune Bio Quantum Biopharma Ikena Oncology Verrica Pharmaceuticals ImmuCell Werewolf Therapeutics MediciNova Gelteq (NASDAQ:GELS) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk. Which has preferable valuation and earnings, GELS or CUE? Gelteq has higher earnings, but lower revenue than Cue Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGelteqN/AN/A-$2.33MN/AN/ACue Biopharma$9.29M7.16-$40.67M-$0.67-1.32 Is GELS or CUE more profitable? Gelteq has a net margin of 0.00% compared to Cue Biopharma's net margin of -507.87%. Gelteq's return on equity of 0.00% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets GelteqN/A N/A N/A Cue Biopharma -507.87%-228.43%-114.66% Do analysts prefer GELS or CUE? Cue Biopharma has a consensus price target of $4.00, indicating a potential upside of 353.05%. Given Cue Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Cue Biopharma is more favorable than Gelteq.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to GELS or CUE? In the previous week, Gelteq and Gelteq both had 1 articles in the media. Cue Biopharma's average media sentiment score of 1.87 beat Gelteq's score of 0.94 indicating that Cue Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Gelteq Positive Cue Biopharma Very Positive Do insiders & institutionals believe in GELS or CUE? 35.0% of Cue Biopharma shares are held by institutional investors. 10.8% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryCue Biopharma beats Gelteq on 7 of the 11 factors compared between the two stocks. Get Gelteq News Delivered to You Automatically Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GELS vs. The Competition Export to ExcelMetricGelteqMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.65M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.60%4.01%P/E RatioN/A21.1828.1020.05Price / SalesN/A286.99429.3789.38Price / CashN/A42.7636.2258.56Price / Book1.478.378.665.87Net Income-$2.33M-$55.19M$3.25B$258.55M7 Day Performance4.95%5.88%4.22%3.73%1 Month Performance1.60%17.33%10.51%11.75%1 Year PerformanceN/A4.42%34.40%18.03% Gelteq Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GELSGelteqN/A$1.91+2.1%N/AN/A$17.65MN/A0.00N/ACUECue Biopharma4.0437 of 5 stars$0.91+1.7%$3.00+231.5%+25.5%$68.19M$9.29M-1.3560Positive NewsOTLKOncobiologics2.2591 of 5 stars$2.02-2.9%$9.60+375.2%-75.5%$67.98MN/A-2.2320News CoverageRPTXRepare Therapeutics2.6591 of 5 stars$1.56+2.0%$4.50+188.5%-60.0%$66.48M$53.48M-0.51180Positive NewsINMBINmune Bio2.3077 of 5 stars$2.83-1.0%$18.40+549.9%-68.0%$66.38M$10K-1.4610Positive NewsUpcoming EarningsQNTMQuantum BiopharmaN/A$22.41-1.0%N/AN/A$65.10MN/A-1.40N/AIKNAIkena Oncology2.827 of 5 stars$1.34-2.9%$3.00+123.9%-14.9%$64.91M$9.16M-1.5670News CoveragePositive NewsEarnings ReportAnalyst ForecastStock SplitVRCAVerrica Pharmaceuticals3.9464 of 5 stars$0.69-1.8%$8.00+1,056.1%-8.8%$64.37M$7.57M-0.5840Positive NewsGap DownICCCImmuCell0.3111 of 5 stars$7.01+0.9%N/A+58.9%$63.41M$26.49M-100.1970HOWLWerewolf Therapeutics4.0485 of 5 stars$1.38-0.7%$8.33+503.9%-50.4%$61.92M$1.88M-0.8340MNOVMediciNova1.607 of 5 stars$1.27+0.4%$7.00+453.4%+12.3%$61.80MN/A-5.4810News CoverageAnalyst ForecastGap UpHigh Trading Volume Related Companies and Tools Related Companies Cue Biopharma Competitors Oncobiologics Competitors Repare Therapeutics Competitors INmune Bio Competitors Quantum Biopharma Competitors Ikena Oncology Competitors Verrica Pharmaceuticals Competitors ImmuCell Competitors Werewolf Therapeutics Competitors MediciNova Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GELS) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
